The METRIC trial: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients with metastatic gpNMB-overexpressing triple negative breast cancer (TNBC)

被引：2
|
作者：
Melisko, M.
Yardley, D. A.
Blackwell, K.
Forero, A.
Ma, C.
Montero, A.
Daniel, B. R.
Wright, G.
Fehrenbacher, L.
Chew, H.
Ferrario, C.
Nanda, R.
Seiler, M., Jr.
Guthrie, T.
Vance, K.
Ouellette, G.
He, Y.
Bagley, R. G.
Zhang, J.
Vandat, L. T.
机构：
[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[2] Tennessee Oncol PLLC, Sarah Cannon Res Inst, New York, NY USA
[3] Duke Univ, Med Ctr, Durham, NC 27706 USA
[4] Univ Alabama, Tuscaloosa, AL 35487 USA
[5] Washington Univ, St Louis, MO 63130 USA
[6] Cleveland Clin, Cleveland, OH USA
[7] Univ Calif Davis, Comprehens Canc Ctr, Davis, CA USA
[8] Jewish Gen Hosp, Segal Canc Ctr, New York, NY USA
[9] Univ Chicago, Chicago, IL 60637 USA
[10] Crescent City Res Consortium LLC, New York, NY USA
[11] Baptist Canc Inst, London, England
[12] Weill Cornell Med Coll, New York, NY USA
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-OT1-03-15
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-03-15
引用
收藏
页数：2
相关论文
共 30 条
  • [1] METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC).
    Yardley, Denise A.
    Melisko, Michelle E.
    Forero, Andres
    Daniel, Brooke R.
    Montero, Alberto J.
    Guthrie, Troy H.
    Canfield, Vikki A.
    Oakman, Catherine Angela
    Chew, Helen K.
    Ferrario, Cristiano
    Volas-Redd, Gena H.
    Young, Robyn R.
    Henry, Norah Lynn
    Aneiro, Lynn
    He, Yi
    Turner, Christopher D.
    Davis, Thomas A.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)
    Schmid, P.
    Melisko, M.
    Yardley, D. A.
    Blackwell, K.
    Forero, A.
    Ouellette, G.
    He, Y.
    Bagley, R. G.
    Zhang, J.
    Vahdat, L. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC)
    Vahdat, L. T.
    Forero-Torres, A.
    Schmid, P.
    Blackwell, K.
    Telli, M. L.
    Melisko, M.
    Holgado, E.
    Moebus, V.
    Cortes, J.
    Fehrenbacher, L.
    Montero, A. J.
    Ma, C.
    Nanda, R.
    Wright, G. S.
    He, Y.
    Bagley, R. G.
    Halim, A.
    Turner, C. D.
    Yardley, D. A.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study
    Yardley, D. A.
    Weaver, R.
    Melisko, M. E.
    Saleh, M. N.
    Arena, F. P.
    Forero, A.
    Cigler, T.
    Stopeck, A.
    Citron, D.
    Oliff, I.
    Bechhold, R.
    Loutfi, R.
    Garcia, A.
    Crowley, E.
    Green, J.
    Yellin, M. J.
    Davis, T. A.
    Vandat, L. T.
    CANCER RESEARCH, 2012, 72
  • [5] The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer
    Keir, Christopher H.
    Vahdat, Linda T.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (02) : 259 - 263
  • [6] Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study
    Vahdat, Linda T.
    Schmid, Peter
    Forero-Torres, Andres
    Blackwell, Kimberly
    Telli, Melinda L.
    Melisko, Michelle
    Mobus, Volker
    Cortes, Javier
    Montero, Alberto J.
    Ma, Cynthia
    Nanda, Rita
    Wright, Gail S.
    He, Yi
    Hawthorne, Thomas
    Bagley, Rebecca G.
    Halim, Abdel-Baset
    Turner, Christopher D.
    Yardley, Denise A.
    NPJ BREAST CANCER, 2021, 7 (01)
  • [7] Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study
    Linda T. Vahdat
    Peter Schmid
    Andres Forero-Torres
    Kimberly Blackwell
    Melinda L. Telli
    Michelle Melisko
    Volker Möbus
    Javier Cortes
    Alberto J. Montero
    Cynthia Ma
    Rita Nanda
    Gail S. Wright
    Yi He
    Thomas Hawthorne
    Rebecca G. Bagley
    Abdel-Baset Halim
    Christopher D. Turner
    Denise A. Yardley
    npj Breast Cancer, 7
  • [8] A pivotal multicenter, randomized, study evaluating the novel antibody-drug conjugate CDX-011 in patients with metastatic, triple-negative, high GPNMB over-expressing breast cancer
    Yardley, D. A.
    Melisko, M. E.
    Forero, A.
    Telli, M.
    Cruickshank, S.
    Green, J.
    Yellin, M.
    Davis, T.
    Vahdat, L. T.
    CANCER RESEARCH, 2013, 73
  • [9] Management of Metastatic Breast Cancer with Second-Generation Antibody-Drug Conjugates: Focus on Glembatumumab Vedotin (CDX-011, CR011-vcMMAE)
    Vaklavas, Christos
    Forero, Andres
    BIODRUGS, 2014, 28 (03) : 253 - 263
  • [10] Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody-drug conjugate (ADC), CDX-011 (CRX011-vcMMAE)
    Saleh, M. N.
    Bendell, J. C.
    Rose, A.
    Siegel, P.
    Hart, L. L.
    Sirpal, S.
    Jones, S. F.
    Crowley, E.
    Simantov, R.
    Vahdat, L. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
123